Triple procedure preferred over staged approach for DSAEK and cataract removal

Article

With proper technique, Descemet's stripping automated endothelial keratoplasty (DSAEK) with phacoemulsification is not any riskier than DSAEK alone, said Mark A. Terry, MD, director of cornea services, Devers Eye Institute, Portland, OR.

With proper technique, Descemet's stripping automated endothelial keratoplasty (DSAEK) with phacoemulsification is not any riskier than DSAEK alone, said Mark A. Terry, MD, director of cornea services, Devers Eye Institute, Portland, OR.

Dr. Terry presented outcomes from DSAEK cases being followed prospectively in an ongoing IRB-approved study at the institute. The series includes 223 eyes, of which 52% underwent a triple procedure with DSAEK, phacoemulsification, and IOL implantation.

Results showed that in the entire series of 223 eyes where an ophthalmic viscosurgical device (OVD) (Healon, Advanced Medical Optics) was used in all procedures, the donor dislocation rate was very low (1.3%). Dislocation rates were similar comparing eyes that underwent DSAEK alone with those that had triple surgery, and there was also no evidence that DSAEK combined with cataract surgery increased endothelial cell loss measured at 6 months. There were no cases of primary graft failure in the entire series of 223 eyes, precluding any analysis of the effect of triple surgery on that outcome.

"Some surgeons advocate doing phacoemulsification first and DSAEK weeks later based on a concern about residual viscoelastic promoting graft dislocation and fear that the newly placed IOL will be unstable and touch the graft, causing endothelial damage," Dr. Terry said. "However, a combined procedure reduces cost, time and risk for the patient, and our data present an evidence based-rationale for combining DSAEK with phacoemulsification in eyes with significant Fuchs dystrophy and cataract formation."

He noted that initial laboratory studies were performed to investigate the suitability of the OVD use during DSAEK. Their results confirmed 1) the extremely cohesive nature of the OVD does not allow it to coat the anterior chamber surface, and 2) the OVD is easily and completely removed from the anterior chamber surface with a simple I/A technique.

In order to prevent graft-IOL touch, Dr. Terry emphasized creating a small diameter (4.5 mm or less) capsulorhexis to secure the IOL in the capsular bag and to constrict the pupil pharmacologically prior to insertion of the graft.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.